Results 221 to 230 of about 280,195 (357)

Effect of Valemetostat on the Pharmacokinetics of Midazolam and Digoxin: A Phase 1 Drug-Drug Interaction Study in Patients With Non-Hodgkin Lymphoma. [PDF]

Clin Transl Sci
Tachibana M, Horwitz S, Jacobsen E, Foss F, Allen P, Porcu P, Feldman T, Ruan J, Brammer JE, Wang J, Inaba S, Iko Y, Nakajima K, Kakurai Y, Kitami N, Chen Y, Lau Y.   +16 more
europepmc   +1 more source

HLA-G+3027 polymorphism is associated with tumor relapse in pediatric Hodgkin's lymphoma [PDF]

, 2017
Bianchi, Maurizio, Buffardi, Salvatore, Burnelli, Roberta, Caggiari, Laura, Carosella, Edgardo D., D'Amore, Emanuele Stefano, DE ZORZI, Mariangela, Elia, Caterina, Famengo, Barbara, Farruggia, Piero, Martina, Lia, Mascarin, Maurizio, Muggeo, Paola, Mussolin, Lara, Pillon, Marta, Re, Valli, Sala, Alessandra, Santoro, Nicola, Vinti, Luciana   +18 more
core   +1 more source

Revised International Pediatric Non-Hodgkin Lymphoma Staging System.

Journal of Clinical Oncology, 2015
Angelo Rosolen, S. Perkins, C. Pinkerton, R. P. Guillerman, J. Sandlund, C. Patte, A. Reiter, M. Cairo   +7 more
semanticscholar   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Behçet's Disease in a Patient With Non-Hodgkin Lymphoma: A Case of Genital Ulceration Resembling a Sexually Transmitted Disease. [PDF]

Cureus
Arkania N, Rahma Wijayanti R, Kus Megawati F, Fauziyah R, Febriana SA.   +4 more
europepmc   +1 more source

Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead.

Journal of Clinical Oncology, 2015
V. Minard-Colin, L. Brugières, A. Reiter, M. Cairo, T. Gross, W. Woessmann, B. Burkhardt, J. Sandlund, Denise Williams, M. Pillon, K. Horibe, A. Aupérin, M. le Deley, M. Zimmerman, S. Perkins, M. Raphael, L. Lamant, W. Klapper, L. Mussolin, H. Poirel, E. Macintyre, C. Damm-Welk, Angelo Rosolen, C. Patte   +23 more
semanticscholar   +1 more source

Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions

Clinical Endocrinology, EarlyView.
ABSTRACT Objective To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT). Design The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data. Patients The review focuses
Annice Mukherjee, Susan R. Davis
wiley   +1 more source

Non-Hodgkin lymphoma: diagnosis and treatment.

Mayo Clinic proceedings, 2015
S. Ansell, J. Armitage
semanticscholar   +2 more sources

Immunosenescence phenotypes and prognostic significance of CD8 + CD28- T cells in AIDS-related non-Hodgkin lymphoma. [PDF]

Ann Med
Kang Z, Tao X, Wu S, Chu S, Peng J, Chen J.   +5 more
europepmc   +1 more source

Identification of miR-155 targets to elucidate the role of high miR-155 levels in B cell Hodgkin and non-Hodgkin lymphoma

, 2007
Johan H. Gibcus, Rikst Nynke Schakel, Geertruida Harms, Joost Kluiver, Naoyuki Kamatani, S. Popperna, Bart Jan Kroesen, van den Arie Berg   +7 more
openalex   +1 more source